A Single-Arm Phase II Clinical Study of Sacituzumab Tirumotecan Combined With a PD-1 Inhibitor as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma After Failure of or Progression on Immunotherapy
This study is a single-center, single-arm, prospective clinical study enrolling a total of 30 patients with advanced metastatic esophageal squamous cell carcinoma who have failed or progressed after prior first-line immunotherapy or immunotherapy combined with chemotherapy.
After signing the informed consent form, subjects will undergo screening assessment within 28 days prior to the first dose to determine whether they meet the study requirements. Subjects who meet the study inclusion and exclusion criteria will receive sacituzumab tirumotecan and a PD-1 inhibitor.
Patients will receive sacituzumab tirumotecan (4 mg/kg IV d1 Q2W) in combination with a PD-1 inhibitor for 6 cycles, followed by maintenance therapy with a PD-1 inhibitor-based regimen.
until investigator-confirmed radiological disease progression, unacceptable toxicity, the subject's request to discontinue treatment, or other protocol-specified criteria for treatment discontinuation, whichever occurs first; Eligible subjects will undergo regular tumor assessments based on RECIST 1.1. Within 48 weeks (within the first year) after dosing, imaging examinations for tumor assessment will be performed every 6 weeks (±7 days); after 48 weeks, tumor assessment will be performed every 12 weeks (±7 days), until radiological disease progression, initiation of new anti-tumor therapy, withdrawal of informed consent by the subject, loss to follow-up, death, or termination of the study by the sponsor, whichever occurs first. Imaging examinations will be performed as scheduled regardless of dose delay or adjustment. After a patient first achieves complete response (CR) or partial response (PR), the observed response must be confirmed at least 4 weeks (28 days) later.
For subjects who discontinue treatment for reasons other than radiological disease progression, death or loss to follow-up, imaging examinations should be repeated at the EOT visit if more than 4 weeks have elapsed since the previous imaging examination; subsequent imaging examinations should be performed as scheduled as far as possible until radiological disease progression, initiation of new anti-tumor therapy, withdrawal of informed consent by the subject, loss to follow-up, death, or termination of the study by the sponsor, whichever occurs first.
After the end of treatment, regardless of whether a new anti-tumor therapy is initiated, safety follow-up must be completed for the subject, and survival follow-up visits will be continued by telephone every 3 months (±14 days) after the last dose of study treatment to obtain survival information and information on new anti-tumor therapy, until the subject decides to withdraw from the study, loss to follow-up, death, or the end of the study, whichever occurs first.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Rui Liu
- Numero di telefono: 022 23340123
- Email: liurui9003@163.com
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Histopathologically confirmed unresectable advanced metastatic esophageal squamous cell carcinoma;
- Age 18-75 years, male or female;
- At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (iRECIST 1.1); measurable lesions should not have received prior local therapy such as radiotherapy;
- Failure (disease progression or unacceptable toxicity) of prior first-line immunotherapy or immunotherapy combined with chemotherapy; patients who relapse within 6 months after the end of adjuvant/neoadjuvant therapy, if the treatment regimen was immunotherapy or immunotherapy combined with chemotherapy, will be regarded as having failed first-line treatment and may be enrolled;
- Expected survival of ≥12 weeks;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before dosing;
- Radiologically confirmed disease progression during or after the most recent treatment for advanced or metastatic disease;
- Adequate organ and bone marrow function (no blood transfusion, recombinant human thrombopoietin or colony-stimulating factor within 2 weeks prior to the first dose)
- Female subjects of childbearing potential and male subjects whose partners are of childbearing potential must agree to use effective medical contraception from the signing of the informed consent form until 6 months after the last dose; 10) Subjects voluntarily participate in this study, sign the informed consent form, and are able to comply with the visits and related procedures specified in the protocol.
Exclusion Criteria:
- Subjects with known meningeal metastasis, brainstem metastasis, spinal metastasis and/or compression, or active or untreated central nervous system (CNS) metastasis. Subjects with brain metastasis who have received prior local therapy may be enrolled if they are clinically stable for at least 4 weeks before dosing and do not require glucocorticoids or anticonvulsants for at least 14 days;
- Patients who experienced disease progression within 3 months during prior first-line treatment;
- Prior receipt of TROP2-targeted therapy; prior receipt of any topoisomerase I inhibitor drug or chemotherapy;
- Presence of persistent or active infection;
- Participation in other anti-tumor drug clinical trials within 4 weeks before screening;
- Presence of adverse events of CTCAE > Grade 1 before the first dose (excluding alopecia and endocrine toxicity);
- Presence of other uncured malignancies within 5 years (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
- Positive human immunodeficiency virus (HIV) test or a history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection;
- Known hypersensitivity to the study drug or any of its components;
- History of (non-infectious) interstitial lung disease (ILD) or non-infectious pneumonitis requiring steroid treatment, current ILD or non-infectious pneumonitis, or suspected ILD or non-infectious pneumonitis that cannot be excluded by imaging examination at screening;
- Poorly controlled diabetes mellitus (fasting blood glucose ≥ 10 mmol/L on two consecutive measurements);
- Presence of clinically symptomatic pleural effusion, pericardial effusion or ascites requiring repeated drainage (> once per week);
- Documented severe dry eye syndrome, severe meibomian gland disease and/or blepharitis, or a history of corneal disease that prevents or delays corneal healing; Any condition that, in the investigator's judgment, interferes with the evaluation of the study drug, the safety of the subject or the interpretation of study results, or any other condition considered by the investigator to make the subject unsuitable for participation in this study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Sacituzumab tirumotecan combined with PD-1 inhibitor
Patients will receive sacituzumab tirumotecan (4 mg/kg IV d1 Q2W) in combination with a PD-1 inhibitor for 6 cycles, followed by maintenance therapy with a PD-1 inhibitor-based regimen. |
Patients will receive sacituzumab tirumotecan (4 mg/kg IV d1 Q2W) in combination with a PD-1 inhibitor for 6 cycles, followed by maintenance therapy with a PD-1 inhibitor-based regimen.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
progression-free survival (PFS)
Lasso di tempo: 2years
|
To evaluate progression-free survival (PFS) with sacituzumab tirumotecan combined with a PD-1 inhibitor: the time from enrollment to radiologically confirmed disease progression (PD) (per iRECIST 1.1) or death from any cause without documented progression; |
2years
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
objective response rate (ORR)
Lasso di tempo: 1year
|
To evaluate the objective response rate (ORR) of sacituzumab tirumotecan combined with a PD-1 inhibitor: per iRECIST 1.1, the proportion of patients whose best overall response from enrollment to disease progression is CR or PR among all evaluable patients; |
1year
|
|
overall survival (OS)
Lasso di tempo: 3years
|
To evaluate overall survival (OS) with sacituzumab tirumotecan combined with a PD-1 inhibitor: the time from enrollment to death from any cause; |
3years
|
|
duration of response (DOR)
Lasso di tempo: 1year
|
To evaluate the duration of response (DOR) with sacituzumab tirumotecan combined with a PD-1 inhibitor: the time from the first assessment meeting CR or PR criteria to the observation of PD or death, whichever occurs first; calculated only for patients whose best overall response is CR or PR |
1year
|
|
adverse events (AEs)
Lasso di tempo: 2years
|
During this study and the follow-up period, the severity of adverse events will be graded and assessed according to NCI CTCAE (version 5.0). Safety evaluation indicators include: The incidence, severity and relationship to the study drug of all adverse events (AEs), treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs); The number and proportion of subjects with dose reduction and treatment discontinuation due to the above adverse events; Changes in vital signs, physical examination findings and laboratory results before, during and after study treatment. |
2years
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Neoplasie per tipo istologico
- Neoplasie gastrointestinali
- Neoplasie dell'apparato digerente
- Malattie dell'apparato digerente
- Malattie gastrointestinali
- Neoplasie della testa e del collo
- Neoplasie, ghiandolari ed epiteliali
- Malattie esofagee
- Carcinoma
- Neoplasie, cellule squamose
- Carcinoma, cellule squamose
- Neoplasie esofagee
- Carcinoma a cellule squamose dell'esofago
- Agenti antineoplastici, immunologici
- Agenti antineoplastici
- Meccanismi molecolari dell'azione farmacologica
- Azioni farmacologiche
- Azioni e usi chimici
- Usi terapeutici
- Inibitori del checkpoint immunitario
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- E20261246
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .